Early this month, I went to Washington, D.C., to serve as a witness for a hearing on “Examining Patient Access to Investigational Drugs” held by the Subcommittee on Health of the House of Representatives’ Committee on Energy and Commerce. The Subcommittee on Health called several others as witnesses, including a veteran with ALS, a biotech CEO, a patient advocate, the commissioner of the FDA, and the U.S. Government Accountability Office’s director for health care. While the topic — patient access to experimental medicines — was broad, the de facto purpose of the hearing was to talk about right to try laws.